Profile Page

This promotional site is only intended for UK healthcare professionals.
This promotional site is only intended for UK healthcare professionals.
I am not a UK healthcare professional
Adverse Event Reporting
Prescribing Information

Obstructive HCM
About CAMZYOS
- CAMZYOS MoA
- NICE recommendations
Clinical studies
- EXPLORER-HCM
- VALOR-HCM
Efficacy
Safety
Dosing
Resources

My profile Logout

Menu

Obstructive HCM

About obstructive HCM
Identifying patients
Treatment landscape

About CAMZYOS

CAMZYOS MoA
NICE recommendations

Clinical studies

EXPLORER-HCM
VALOR-HCM

Efficacy

EXPLORER-HCM primary endpoint
EXPLORER-HCM secondary endpoints
EXPLORER-HCM exploratory endpoints
VALOR-HCM primary endpoint

Safety

Safety profile
Important information
Drug interactions

Dosing

Dosing and initiation
Maintenance and interruption
Special populations

FAQs

Resources

Obstructive HCM

About obstructive HCM
Identifying patients
Treatment landscape

About CAMZYOS

CAMZYOS MoA
NICE recommendations

Clinical studies

EXPLORER-HCM
VALOR-HCM

Efficacy

EXPLORER-HCM primary endpoint
EXPLORER-HCM secondary endpoints
EXPLORER-HCM exploratory endpoints
VALOR-HCM primary endpoint

Safety

Safety profile
Important information
Drug interactions

Dosing

Dosing and initiation
Maintenance and interruption
Special populations

FAQs

Resources

Obstructive HCM

About obstructive HCM
Identifying patients
Treatment landscape

About CAMZYOS

CAMZYOS MoA
NICE recommendations

Clinical studies

EXPLORER-HCM
VALOR-HCM

Efficacy

EXPLORER-HCM primary endpoint
EXPLORER-HCM secondary endpoints
EXPLORER-HCM exploratory endpoints
VALOR-HCM primary endpoint

Safety

Safety profile
Important information
Drug interactions

Dosing

Dosing and initiation
Maintenance and interruption
Special populations

FAQs

Resources

Obstructive HCM

About obstructive HCM
Identifying patients
Treatment landscape

About CAMZYOS

CAMZYOS MoA
NICE recommendations

Clinical studies

EXPLORER-HCM
VALOR-HCM

Efficacy

EXPLORER-HCM primary endpoint
EXPLORER-HCM secondary endpoints
EXPLORER-HCM exploratory endpoints
VALOR-HCM primary endpoint

Safety

Safety profile
Important information
Drug interactions

Dosing

Dosing and initiation
Maintenance and interruption
Special populations

FAQs

Resources

Obstructive HCM

About obstructive HCM
Identifying patients
Treatment landscape

About CAMZYOS

CAMZYOS MoA
NICE recommendations

Clinical studies

EXPLORER-HCM
VALOR-HCM

Efficacy

EXPLORER-HCM primary endpoint
EXPLORER-HCM secondary endpoints
EXPLORER-HCM exploratory endpoints
VALOR-HCM primary endpoint

Safety

Safety profile
Important information
Drug interactions

Dosing

Dosing and initiation
Maintenance and interruption
Special populations

FAQs

Resources

Obstructive HCM

About obstructive HCM
Identifying patients
Treatment landscape

About CAMZYOS

CAMZYOS MoA
NICE recommendations

Clinical studies

EXPLORER-HCM
VALOR-HCM

Efficacy

EXPLORER-HCM primary endpoint
EXPLORER-HCM secondary endpoints
EXPLORER-HCM exploratory endpoints
VALOR-HCM primary endpoint

Safety

Safety profile
Important information
Drug interactions

Dosing

Dosing and initiation
Maintenance and interruption
Special populations

FAQs

Resources

Obstructive HCM

About obstructive HCM
Identifying patients
Treatment landscape

About CAMZYOS

CAMZYOS MoA
NICE recommendations

Clinical studies

EXPLORER-HCM
VALOR-HCM

Efficacy

EXPLORER-HCM primary endpoint
EXPLORER-HCM secondary endpoints
EXPLORER-HCM exploratory endpoints
VALOR-HCM primary endpoint

Safety

Safety profile
Important information
Drug interactions

Dosing

Dosing and initiation
Maintenance and interruption
Special populations

FAQs

Resources

Obstructive HCM

About obstructive HCM
Identifying patients
Treatment landscape

About CAMZYOS

CAMZYOS MoA
NICE recommendations

Clinical studies

EXPLORER-HCM
VALOR-HCM

Efficacy

EXPLORER-HCM primary endpoint
EXPLORER-HCM secondary endpoints
EXPLORER-HCM exploratory endpoints
VALOR-HCM primary endpoint

Safety

Safety profile
Important information
Drug interactions

Dosing

Dosing and initiation
Maintenance and interruption
Special populations

FAQs

Resources

Code Login

Doccheck

Code Login

Inami Login

Doccheck

Inami Login

Code Login

Inami Login

Login

Error

Success

References

Prescribing Information and Adverse Event reporting information can be accessed using the links on the top right of the page.

Adverse events should be reported. Reporting forms and information can be found at: UK - http://www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Bristol-Myers Squibb via
medical.information@bms.com or 0800 731 1736 (UK).

Legal Notice | Privacy Policy

3500-GB-2300210 | February 2024